AnalystsInsight

Andrew Brackmann (William Blair): Analyst Track Record and Price‑Target Accuracy

Andrew Brackmann is one of the top‑ranked analysts in Exent’s 7‑year backtest. What Andrew covers, how Andrew’s ratings lean, how fast price targets were reached and the ratings from before the last 30 days; the full record and the newest calls are members‑only.

Published Updated 2 min readHow we research

Key takeaways

  • Andrew Brackmann ranks among the top 50 healthcare analysts in Exent’s ranking, scored on a 7‑year backtest.
  • The exact rank, price‑target hit rate and live calls are members‑only in Exent Gems.
  • Most‑covered stocks: GH, NEO, QDEL, ADPT.
  • In the past year Andrew’s ratings were 66% Buy, 34% Hold and 0% Sell.

Andrew Brackmann’s track record at a glance

Andrew Brackmann of William Blair ranks among the top 50 healthcare analysts in Exent’s ranking, with a focus on healthcare. The top of the ranking is what Exent Gems follows, so Andrew’s exact rank, hit rate and live calls are for members.

MetricAndrew BrackmannAll analysts
Exent rank—
Price‑target hit rate52.4%
Calls up after 12 months64.0%
Median 12‑month return of calls+13.4%
Median days to hit target91 days
Stocks covered22—

How fast price targets were reached

Time to reach the targetAndrew Brackmann
Under 30 days66.7%
30–90 days33.3%
90–180 days0.0%
Over 180 days0.0%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Andrew Brackmann covers most

GH · NEO · QDEL · ADPT · TEM · BFLY · VCYT · SERA

In the past year Andrew’s ratings were 66% Buy, 34% Hold and 0% Sell.

Andrew Brackmann’s latest ratings

DateStockActionRatingPrice target
Jul 2, 2026BDXRated: HoldHold$0.00
Jul 2, 2026XGNRated: HoldHold$0.00
Jul 2, 2026QDELRated: HoldHold$0.00
Jun 18, 2026BFLYMaintained: Buy—$0.00
Jun 18, 2026BFLYReiterated: BuyBuy$0.00
Jun 16, 2026ADPTReiterated: BuyBuy$0.00
Jun 15, 2026DGXMaintained: BuyBuy$0.00
Jun 15, 2026DGXReiterated: BuyBuy$0.00
Jun 1, 2026TEMReiterated: HoldHold$0.00
Jun 1, 2026TEMReiteratedHold—
May 27, 2026GHReiterated: BuyBuy$0.00
May 27, 2026NEOMaintainedHold—
  • Jul 2, 2026
    Stock
    BDX
    Action
    Rated: Hold
    Rating
    Hold
    Price target
    $0.00
  • Jul 2, 2026
    Stock
    XGN
    Action
    Rated: Hold
    Rating
    Hold
    Price target
    $0.00
  • Jul 2, 2026
    Stock
    QDEL
    Action
    Rated: Hold
    Rating
    Hold
    Price target
    $0.00
  • Jun 18, 2026
    Stock
    BFLY
    Action
    Maintained: Buy
    Rating
    —
    Price target
    $0.00
  • Jun 18, 2026
    Stock
    BFLY
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Jun 16, 2026
    Stock
    ADPT
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Jun 15, 2026
    Stock
    DGX
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $0.00
  • Jun 15, 2026
    Stock
    DGX
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Jun 1, 2026
    Stock
    TEM
    Action
    Reiterated: Hold
    Rating
    Hold
    Price target
    $0.00
  • Jun 1, 2026
    Stock
    TEM
    Action
    Reiterated
    Rating
    Hold
    Price target
    —
  • May 27, 2026
    Stock
    GH
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • May 27, 2026
    Stock
    NEO
    Action
    Maintained
    Rating
    Hold
    Price target
    —

Ratings from the last 30 days are members‑only in Exent Gems, with the stocks where several top‑ranked analysts agree; older ratings are shown in full.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 20, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Andrew Brackmann’s full record and latest ratings, without the 30‑day delay.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring, Andrew Brackmann ranks among the top 50 healthcare analysts in Exent’s ranking, based on a 7-year backtest of price-target hit rate, returns after calls and number of ratings. The exact rank, hit rate and live calls are members-only in Exent Gems (exent.ai/radar). Past accuracy does not guarantee future accuracy.

Andrew Brackmann’s price-target hit rate is part of the members-only record in Exent Gems (exent.ai/radar). For comparison, the average analyst’s price targets were reached 52.4% of the time.

Andrew Brackmann (William Blair) covers 22 stocks, mostly in healthcare. The most frequently rated are GH, NEO, QDEL, ADPT, TEM.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.